| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Lee Troy Schalop is Director at LTRN. Lee Troy Schalop's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $29K at current prices.
Net of sales, the LTRN filings show accumulation of 48,544 shares.
Lee Troy Schalop has 3 Form 4 filings on record from August 2025 to May 2026, all as Director at Lantern Pharma (LTRN), 2025–2026.
The 5 reported transactions were 3 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $100K and no sales.
The only open-market purchase was 48,544 shares of LTRN at an average $2.06 on May 12, 2026, about $100K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | LTRN Lantern Pharma Inc. | Director | Buy | 48,544 | $2.06 | $100,000.64 | New | +36.4% | - |